Optimization of the Manufacturing Route to PF-610355 (2): Synthesis of the API
PF-610355 is a novel inhaled β-2 adrenoreceptor agonist. Process development of the final intermediate and the API are discussed with emphasis on the control of physical properties and subsequent isolations.
Unit Operation: Distillation, Drying
Objective: Optimization
Company: Pfizer
Source: Org. Process Res. Dev., 2013, 17 (2), pp 202–212
Authors: Stéphane Content (Pfizer), Thomas Dupont (Pfizer), Nicolas M. Fédou (Pfizer), Julian D. Smith (Pfizer), Christopher Stoneley (Pfizer), Flavien Susanne (Pfizer), Steven J. R. Twiddle (Pfizer)
Publish Date: 05-Feb-2013
Copyright © 2019 Scale-up Systems Ltd. | DynoChem Software and Development Services for the Pharma Industry | Privacy | Cookies | Contact